ENJAYMO

Indicated For

Cold Agglutinin Disease, hemolytic anemia

About This Medication

# ENJAYMO Patient Solutions Patient Guide: How to Get ENJAYMO (sutimlimab-jome) at Low or No Cost ENJAYMO (sutimlimab-jome) is a prescription medicine used to treat adults with cold agglutinin disease (CAD), a rare type of autoimmune hemolytic anemia where cold temperatures trigger red blood cell destruction, leading to fatigue, shortness of breath, and anemia.[5][10] The **ENJAYMO Patient Solutions** program from **Recordati Rare Diseases** helps eligible patients access this in-office, infusion center, or at-home treatment at little or no cost through options like copay assistance, a no-cost trial, and patient assistance for uninsured or underinsured individuals.[1][2][3] ## Who Qualifies for ENJAYMO Patient Solutions? This program offers multiple pathways to make **ENJAYMO** affordable. It's designed for adults (18+) with CAD living in the US, Puerto Rico, or US territories, treated by a US healthcare provider for an on-label use.[2] Key eligibility varies by sub-program: - **Copay Assistance Program**: Helps with out-of-pocket copays, coinsurance, and infusion costs—up to **$25,000 annually**. Patients may pay as little as **$0**. Available **regardless of insurance**, but **not valid** for government programs like Medicare, Medicaid, VA, DoD, TRICARE, or state pharmaceutical assistance.[1][3] - **No Cost Trial Program**: Provides a **30-day supply at no cost** for first-time users. No insurance obligation, and no commitment to continue after the trial.[2][3][6] - **Patient Assistance Program**: Free medication for uninsured or underinsured patients facing financial or insurance barriers. Requires income verification.[4][8] Approval isn't guaranteed, and Recordati reserves the right to change or end the program.[1][3] Always confirm details upon enrollment. ## About ENJAYMO (sutimlimab-jome) **ENJAYMO** is a monoclonal antibody given by IV infusion that targets the C1s protein in the complement system, blocking cold-induced red blood cell destruction in CAD.[5] It's for adults with confirmed CAD, shown by chronic hemolysis, specific blood tests (e.g., cold agglutinin titer ≥64 at 4°C, hemoglobin ≤10 g/dL), and no other causes like infections or lupus.[5][10] Typical dosing: Weekly infusions for two doses, then every 2 weeks. Patients need vaccinations against encapsulated bacteria (e.g., pneumococcus, meningococcus) before starting.[10] Common delivery: In-office, infusion centers, or **at-home via CVS Pharmacy**.[1] Your doctor determines the best method based on coverage and needs. ## Income Eligibility Breakdown Specific income thresholds aren't publicly listed (null in program details), but the Patient Assistance Program requires **income verification** for those with limited access due to finances.[4][8] Copay and trial programs have broader eligibility without strict income caps.[2] Here's a general guide based on similar programs and requirements: | Program Type | Income Requirements | Insurance Status | Max Benefit | |---------------------------|--------------------------------------|-------------------------------|------------------------------| | **Copay Assistance** | None specified; financial need reviewed | Commercial only (no gov't) | $25,000/year[3] | | **No Cost Trial** | None; first-time use, 18+ | Any | 30-day supply[2] | | **Patient Assistance** | Verification required (e.g., W-2, 1040, paystubs)[8] | Uninsured/underinsured | Free meds if eligible[4] | Contact the program for your situation—they assess case-by-case.[1] ## Insurance Requirements - **Commercial insurance**: Eligible for copay help (up to $25,000 savings).[3] - **No insurance/underinsured**: Patient Assistance or No Cost Trial.[2][4] - **Government insurance** (Medicare, Medicaid, etc.): **Not eligible** for copay program. Explore Medicare Extra Help for low-income support separately.[1][3][7] Attach insurance cards (front/back) to enrollment.[8] Program works alongside coverage where allowed. ## Step-by-Step Application Process Applications start **by phone** at **1-833-223-2428** (8AM-5PM ET, Mon-Fri).[1][8] Or download/fax the enrollment form.[8] Here's how: 1. **Talk to your doctor**: Confirm ENJAYMO prescription and CAD diagnosis. Doctor or authorized agent signs form.[8] 2. **Call ENJAYMO Patient Solutions**: 1-833-223-2428. Discuss eligibility for copay, trial, or assistance.[1] 3. **Complete enrollment form**: Provide name, DOB, last 4 SSN digits, address, income docs (W-2, 1040, 2 paystubs for assistance), insurance copies.[8] 4. **Fax form**: To 888-241-3572.[8] 5. **Await approval**: Program reviews and notifies you.[1] 6. **Start treatment**: Receive via chosen infusion method.[1] Your doctor may handle parts of this.[1] ## Timeline and Delivery Processing time isn't specified, but expect review after submission—call for status.[1] Once approved: - **No Cost Trial**: 30-day supply quickly.[2] - Copay card activates fast for pharmacy/infusion. - **Delivery**: In-office (doctor's office), infusion center, or **at-home infusion through CVS Pharmacy**.[1] Home option subject to coverage/physician approval. Refills/reauthorization: Ongoing for copay (up to annual max); assistance may need periodic checks (details on enrollment).[3][8] ## Alternatives if Denied - **Appeal**: Ask program for reasons and resubmit docs.[1] - **Other assistance**: Medicare Extra Help if low-income (covers Part D copays).[7] State programs or general CAD foundations. - **Manufacturer alternatives**: Check Recordati for updates.[4] - **Generic/biosimilars**: None available (null).[5] - **Clinical trials** or payer appeals for CAD treatments like rituximab.[10] ## Disclaimer This guide is for informational purposes based on available program details as of latest data. Eligibility, benefits, and terms can change—Recordati may modify/terminate anytime without notice.[1][3] Not valid where prohibited by law. Consult your doctor, call 1-833-223-2428 for personalized advice, and review full terms upon registration. Approval not guaranteed. This is not medical or financial advice.

Program information last verified: March 30, 2026